Epic’s native AI push squeezes standalone vendors
The gist
Health systems are slashing standalone AI vendors as Epic’s embedded AI stack surges, turning consolidation into survival mode for point solutions.
What to know
- Black Book projects health systems will cut standalone AI vendors nearly in half by 2028 as operational readiness lags and Epic’s native AI expands.
- Healthcare AI spending soared to $3.7 billion in 2026—up 2.5x year over year—while procurement cycles stretched from 7 to 10 months amid tougher ROI scrutiny.
- Epic’s built-in AI tools, like Penny and Art, are delivering clear wins (e.g., 42% faster prior auth, 92% acceptance rates), making it easier for systems to ditch third-party solutions.
Operational Gaps Drive Cuts
Health systems’ lack of AI integration and clear success metrics—not industry hype—are fueling the push to shrink standalone vendor rosters.
The late-2026 case for vendor reduction starts with a mismatch between broad AI adoption and weak operational readiness, not with the HIMSS26 commentary that is sometimes cited too loosely. That March analysis offered no Black Book findings, no late-2026 timeframe, and no 2028 vendor-reduction target; even where it said “the outcomes data being cited at HIMSS26 is real and measurable,” citing examples such as prior authorization time cut by 42%, denials reduced by 20%, and $15 billion in prevented claim losses, it did not discuss planned vendor pruning or Epic’s role in displacing suppliers.
What late-2026 research did show was an operationally immature market that helps explain why health systems would later plan to cut vendors: according to LVB, over 90% of health systems had deployed third-party AI solutions, yet only 44% had a dedicated platform for testing them and respondents reported no strong consensus on success metrics. That same survey found 63% said their AI approach was still developing or ad hoc, while Black Book’s September 2026 findings argued the core problem was execution across workflows rather than buying technology, a setup in which realized ROI predictably lags and consolidation pressure builds.
Procurement Scrutiny Reshapes Market
AI buying cycles are lengthening as health systems demand real ROI, leading to consolidation around proven, EHR-linked vendors and leaving startups behind.
Healthcare AI spending reached $3.7 billion in 2026, a 2.5-times increase from the previous year, and that scale is changing purchasing behavior. Menlo Ventures found the average procurement cycle for health systems increased from seven months in 2025 to 10 months in 2026, as buyers moved from speculative adoption to deeper evaluations, pilots, and partner scrutiny before vendors stay in the stack. Growth varied sharply by category, with year-over-year expansion less than doubling for ambient scribing and coding and billing, while clinical copilots grew approximately five-fold to $550 million and patient engagement and front office functions also accelerated.
Where those hurdles are being applied, spending is concentrating around vendors with stronger workflow fit and platform integration. Becker’s Hospital Review said established vendors captured 68% of new spending on AI medical documentation tools in 2026, led by Microsoft Dragon Copilot and Epic’s Art, while Healthcare Dive reported legacy vendors took 68% of new ambient scribing dollars, now hold 46% market share, and AI startups lost 13% share, showing health systems are pruning AI vendors based on actual ROI performance data and consolidating around core EHR-linked platforms.
Back-Office AI Yields Biggest Gains
AI delivers its strongest financial and efficiency returns in revenue cycle management, where automation is rapidly replacing manual work and driving measurable outcomes.
By late 2026, the clearest healthcare AI payoffs were appearing where value could be counted in dollars and cycle times, not just enthusiasm. Bain and Bessemer’s 2026 Healthcare AI ROI Scorecard found Provider Revenue Cycle Management at 4.0x realized ROI and Payer Claims Operations at 3.4x, ahead of Provider Clinical Workflows at 2.9x; it also showed 67% of RCM solutions operating with semi- or fully autonomous agency versus just 4% in clinical workflows, underscoring that the strongest returns were concentrated in back-office functions built for measurable throughput and payment outcomes.
Case studies show why those categories are winning: Ochsner Health and fmol Health said that after they “turned on epic's billing assistant for patients,” they saw “a significant decrease” in patient-bill calls, while Scripps Health’s Shane Tielman “went after cost, not revenue,” using autonomous coding to cut the cost per encounter tied to manual billing work. Providence’s Lisa Johnson said the organization is “finally realizing some of that value and we’re seeing it in real time,” and Becker’s Healthcare cited similarly direct mechanisms, from charts closed “definitely within 24 hours” that speed reimbursement to AI finding lung nodules that “brings revenue into our organization.”
Contracts Demand Hard Proof
Healthcare buyers now require vendors to guarantee economic results and seamless integration, tightening standards and favoring embedded AI solutions.
Buyers are no longer accepting AI contracts built on broad promises; they are rewriting terms around accountable economics and explicit downside cases. Upward Growth says vendors now have to show what happens at 100%, 70%, and 50% of projected outcome, and if ROI still works at 70% attainment, say so; if it does not work below 85%, be honest, because the CFO will run the math themselves.
That tougher posture is pushing organizations toward fewer, more embedded vendors. The Big Unlock described an API-based model already live in over 300 dental organizations in the US, while Black Book found 96% of AI evaluators within medical groups said integration with existing EHR, practice-management and revenue-cycle systems will be a major buying criterion, 58% said disconnected systems create material staff inefficiency, 89% identified payer administrative requirements, prior authorization, reimbursement complexity or claims follow-up as major sources of avoidable work, and 91% identified denials and payment delays as major operational pain points, reinforcing Doug Brown’s view that the technology or outsourcing investment that matters in 2027 is the one that produces a measurable operational result.
Epic’s Platform Moat Expands
Epic’s native AI tools are crowding out competitors by embedding automation directly into workflows, making it nearly impossible for third-party vendors to compete inside Epic environments.
Epic’s native AI push is accelerating replacement because it is no longer just adding features; it is turning the EHR into the place where health systems can build and run workflow automation themselves. Thoughts on Healthcare Markets and Technology reported that HIMSS26 centered on Epic’s embedded Agent Factory, while Epic also brought outcomes data: at Summit Health, Penny cut medication prior authorization submission time by 42% and saw 92% of AI-generated responses accepted without edits; Epic also reports that Art improved the speed of nursing documentation by 85% across 300 organizations, that Penny reduced coding denials by 20%, and that ECU Health saw agents saving staff roughly 20 hours per week, reinforcing that vendors without comparable in-workflow depth are easier to dislodge.
That replacement pressure grows because Epic combines distribution, data, and workflow access that outside vendors struggle to match inside an Epic shop, especially when clinicians “don’t care where it lives, but they sure don’t want to have to access 12 or 15 different things,” and health systems say “we don’t want to have several credentials to log into different” tools. Thoughts on Healthcare Markets and Technology concluded that “Epic is building a platform moat around agentic AI that competitors will find nearly impossible to replicate inside the health system enterprise,” while Epic cites Cosmos with 16.3 billion encounters from over 310 health systems and CoMET foundation models; Becker’s Hospital Review also found buyers acting on that logic, with Emory’s Nabile Safdar saying if a partner can offer a startup’s capability within about 15 months, “it isn’t worth starting with the startup.”




